Skip to main content

NZDUSD bearish below 0.7260

Kiwi reversed losses of previous two weeks and currently testing a critical resistance in the area between 0.7225-60$ .

A 4h candle close above 0.7260$ will open the door to 0.7330-60$ . I prefer going short at current level 0.7235$ and adding another position at 0.7258$ .

Take profit at 0.7125$ , then 0.7080$ ..I see #nzdusd heading back to 0.6950$ area and long term target 0.59$

The pair is also facing tough resistance at 0.7250$ area because of the 200 moving average on the 4h chart.

Popular posts from this blog

5 crypto Investments that will make you a fortune

After 3 month of research based on business model analysis , technical analysis , market sentiment and market trends , I have reached to a decision of making a portfolio of 5 crypto currencies that have a big potential during the next period. It is expected that initial investment will almost have 4x return atleast , which means if you invest 10k , you will have a potential of reaching 50k atleast , there are 2 tokens out of the 5 tokens have a potential for almost 25x return on initial investment. The coins belong to projects from 4 different industries, they are issued by very succesful companies and supported by famouse blockchain creators and advisors.  I will help you create a profitable portfolio and follow up on these investments with weekly updates which will guide you to make the right entry and exit points. Feel free to contact me anytime on twitter @b4borio or email me at boriology@gmail.com

storj update - 1h chart very bullish

Following up on previous analysis  for storj after breaking over bearish trend. Storj reached a high of 0.95$ , retreating back now to 0.84$ . Below is chart for 1h time frame which shows a very strong trendline coming from lows at 0.67$. A break below will be a sign of reversal, we need to keep over that line for a while to keep the bullish move running upwards. Keep following for updates... Follow me on twitter @b4borio

neximmune tatgeting 75$

NexImmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology #nexi is up by 165% today.